CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb 22, 2021–
Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the first-in-man clinical use of the only FDA cleared cold storage device for donor lungs, its LUNGguard™ Donor Lung Preservation System, by Duke University Hospital.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005619/en/
Paragonix Announces First-in-Man use of LUNGguard™ Donor Lung Preservation System by Duke Hospital (Photo: Business Wire)
“Donor lungs are sensitive to injury and the current ice storage of lungs risks cellular injury, especially with the increasing transport distances and times now experienced by lung transplant centers,” said John Haney, MD, MPH, Surgical Director, Duke Lung Transplant. Dr Haney was the implanting transplant surgeon on the first four cases using the LUNGguard system. “Duke Health is committed to pioneering new innovations that benefit transplant patients and changing the way donor lungs are transported has this potential.”
The first-in-the-world use of the LUNGguard system preserved donor lungs for 7 hours on their journey to provide a patient suffering from Idiopathic Pulmonary Fibrosis (IPF) with new lungs. Since the initial first-in-man, the Duke team has performed an additional four lung transplantations using the LUNGguard System. These early cases have demonstrated the versatility of the device in multiple applications including DCD and DBD donors, total ischemic times from 3 hours to 12 hours, and indications varying from emphysema to cystic fibrosis.
The LUNGguard System represents a radical advance from ice and off-the-shelf coolers that has been the standard-of-care for over 50 years of organ transplantation. For the first time, transplant teams have access to an FDA cleared and CE marked hypothermic lung preservation device that can precisely maintain and monitor the environment necessary for donor lungs.
“At Carolina Donor Services, our mission is to maximize the passing of the heroic gift of life from one person to another through organ donation. We are constantly embracing new technologies that will help safeguard organs and ensure better outcomes for those patients waiting for the gift of life,” said Danielle Niedfeldt, President and CEO of Carolina Donor Services, the organ donation organization that supported these cases. “I am honored that our team could be part of the first-in-man use of the LUNGguard system and we are excited by its positive impact in lung transplantation and saving more lives.”
The development of this system has been supported by a collaboration between Paragonix and the Lung Transplant Foundation, a leading lung transplant patient advocacy group. “The LUNGguard device is a project that we have been working on with Paragonix for the past three years, because we saw the critical need for this technology in lung transplantation. To be able to help another IPF patient in the first-in-man case could not have been more significant to me personally,” said Jeffery Goldstein, President and Founder of the Lung Transplant Foundation and lung transplant recipient.
The LUNGguard System is the latest addition to the Paragonix portfolio of organ preservation and transport systems. It is built on the same proven technology architecture as the Paragonix™ SherpaPak Cardiac Transport System, which has been widely adopted for heart transplantation over the past two years. Additionally, Paragonix has FDA cleared and CE marked systems for kidney, liver, and pancreas transplantation.
“Our team at Paragonix strives to provide donor organs and transplant recipients every possible advantage for a second chance at life,” said Lisa Anderson, Ph.D., Founder, President, and COO of Paragonix Technologies. “We are honored to partner with the team at Duke and Carolina Donor Services to reach this incredible milestone and begin making an impact to as many lung transplant patients as possible.”
About Paragonix Technologies
Paragonix Technologies designs, produces, and markets organ preservation and transport devices that safeguard organs during the journey between donor and transplant recipient patients. Our award-winning devices mitigate risk in an otherwise high stakes environment by combining best-in class transplant products with a centralized communication and data transfer app to eable better coordination and efficiency during donor organ procurements. Paragonix SherpaPak™ CTS is the only commercially available FDA-cleared and CE-marked preservation and transport device for adult and pediatric donor hearts destined for transplantation. Paragonix is the sole sponsor of GUARDIAN, the largest international clinical data registry on heart preservation, capturing clinical outcome data on Paragonix SherpaPak™ CTS and all other heart preservation technologies. Paragonix’s LUNGguard™ is the only FDA-cleared and CE-marked cold storage preservation and transport device for donor lungs and was commercially launched in the US and in Europe in December 2020. Paragonix is also developing preservation devices for pancreas, kidney and liver — designed to improve donor organ quality and extend donor organ preservation time.
Follow us on Twitter: @ParagonixSherpa
Connect with us on LinkedIn: Paragonix Technologies
Like Us on Facebook: Paragonix SherpaPak
View source version on businesswire.com:https://www.businesswire.com/news/home/20210222005619/en/
CONTACT: Michael Tajima
(781) 428.4153
[email protected]
www.paragonixtechnologies.com
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: OTHER HEALTH GENERAL HEALTH TECHNOLOGY MEDICAL DEVICES HOSPITALS OTHER TRANSPORT CARDIOLOGY BIOTECHNOLOGY MEDICAL SUPPLIES TRANSPORT PRACTICE MANAGEMENT OTHER TECHNOLOGY HEALTH
SOURCE: Paragonix Technologies
Copyright Business Wire 2021.
PUB: 02/22/2021 11:00 AM/DISC: 02/22/2021 11:01 AM
http://www.businesswire.com/news/home/20210222005619/en
